Emergence of Natural Killer Cell Large Granular Lymphocytes during Gilteritinib Treatment in Acute Myeloid Leukemia with FLT3-ITD Mutation
Abstract
:Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Gilliland, D.G.; Griffin, J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100, 1532–1542. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Thiede, C.; Steudel, C.; Mohr, B.; Schaich, M.; Schakel, U.; Platzbecker, U.; Wermke, M.; Bornhauser, M.; Ritter, M.; Neubauer, A.; et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99, 4326–4335. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Perl, A.E.; Martinelli, G.; Cortes, J.E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M.R.; Larson, R.A.; Ustun, C.; et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N. Engl. J. Med. 2019, 381, 1728–1740. [Google Scholar] [CrossRef] [PubMed]
- Zhang, R.; Shah, M.V.; Loughran, T.P., Jr. The root of many evils: Indolent large granular lymphocyte leukaemia and associated disorders. Hematol. Oncol. 2010, 28, 105–117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Loughran, T.P., Jr. Clonal diseases of large granular lymphocytes. Blood 1993, 82, 1–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, D.H.; Kamel-Reid, S.; Chang, H.; Sutherland, R.; Jung, C.W.; Kim, H.J.; Lee, J.J.; Lipton, J.H. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009, 94, 135–139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mustjoki, S.; Ekblom, M.; Arstila, T.P.; Dybedal, I.; Epling-Burnette, P.K.; Guilhot, F.; Hjorth-Hansen, H.; Hoglund, M.; Kovanen, P.; Laurinolli, T.; et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009, 23, 1398–1405. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kreutzman, A.; Ladell, K.; Koechel, C.; Gostick, E.; Ekblom, M.; Stenke, L.; Melo, T.; Einsele, H.; Porkka, K.; Price, D.A.; et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011, 25, 1587–1597. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, H.; Nakashima, S.; Usuda, M. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients. Int. J. Hematol. 2012, 96, 308–319. [Google Scholar] [CrossRef] [PubMed]
- Ishiyama, K.; Kitawaki, T.; Sugimoto, N.; Sozu, T.; Anzai, N.; Okada, M.; Nohgawa, M.; Hatanaka, K.; Arima, N.; Ishikawa, T.; et al. Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph(+) leukemia patients treated with dasatinib. Leukemia 2017, 31, 203–212. [Google Scholar] [CrossRef] [PubMed]
- Mathew, N.R.; Baumgartner, F.; Braun, L.; O’Sullivan, D.; Thomas, S.; Waterhouse, M.; Muller, T.A.; Hanke, K.; Taromi, S.; Apostolova, P.; et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat. Med. 2018, 24, 282–291. [Google Scholar] [CrossRef] [PubMed]
- Brunner, A.M.; Li, S.; Fathi, A.T.; Wadleigh, M.; Ho, V.T.; Collier, K.; Connolly, C.; Ballen, K.K.; Cutler, C.S.; Dey, B.R.; et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br. J. Haematol. 2016, 175, 496–504. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Burchert, A.; Bug, G.; Fritz, L.V.; Finke, J.; Stelljes, M.; Rollig, C.; Wollmer, E.; Wasch, R.; Bornhauser, M.; Berg, T.; et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J. Clin. Oncol. 2020, JCO1903345. [Google Scholar] [CrossRef]
- Dubois, S.; Conlon, K.C.; Muller, J.R.; Hsu-Albert, J.; Beltran, N.; Bryant, B.R.; Waldmann, T.A. IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56(bright) NK Cells and Increases NK-Cell Cytokine Release Capabilities. Cancer Immunol. Res. 2017, 5, 929–938. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ando, T.; Sano, H.; Yokoo, M.; Kusaba, K.; Kidoguchi, K.; Yamaguchi, K.; Katsuya, H.; Yoshihara, S.; Kubota, Y.; Kojima, K.; et al. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor. Int. J. Hematol. 2020, 112, 249–253. [Google Scholar] [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Izumi, S.; Minami, Y.; Masuda, S.; Utsu, Y.; Sakaida, E.; Aotsuka, N. Emergence of Natural Killer Cell Large Granular Lymphocytes during Gilteritinib Treatment in Acute Myeloid Leukemia with FLT3-ITD Mutation. Reports 2020, 3, 25. https://doi.org/10.3390/reports3030025
Izumi S, Minami Y, Masuda S, Utsu Y, Sakaida E, Aotsuka N. Emergence of Natural Killer Cell Large Granular Lymphocytes during Gilteritinib Treatment in Acute Myeloid Leukemia with FLT3-ITD Mutation. Reports. 2020; 3(3):25. https://doi.org/10.3390/reports3030025
Chicago/Turabian StyleIzumi, Shintaro, Yosuke Minami, Shinichi Masuda, Yoshikazu Utsu, Emiko Sakaida, and Nobuyuki Aotsuka. 2020. "Emergence of Natural Killer Cell Large Granular Lymphocytes during Gilteritinib Treatment in Acute Myeloid Leukemia with FLT3-ITD Mutation" Reports 3, no. 3: 25. https://doi.org/10.3390/reports3030025